NASDAQ:MLTX MoonLake Immunotherapeutics 5/12/2025 Earnings Report $38.54 -1.64 (-4.08%) As of 05/13/2025 04:00 PM Eastern Earnings HistoryForecast MoonLake Immunotherapeutics EPS ResultsActual EPS-$0.63Consensus EPS -$0.76Beat/MissBeat by +$0.13One Year Ago EPS-$0.22MoonLake Immunotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoonLake Immunotherapeutics Announcement DetailsQuarterDate5/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile MoonLake Immunotherapeutics Earnings HeadlinesMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 13 at 3:18 AM | finanznachrichten.deDecoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT InsightMay 13 at 12:08 AM | gurufocus.comWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, May 14. And as Fortune has written, this IPO is “larger than any IPO valuation in history”… May 14, 2025 | Paradigm Press (Ad)MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy RatingMay 12 at 7:54 PM | tipranks.comMoonLake Immunotherapeutics (MLTX) Strengthens Financial Position with New Funding | MLTX Stock NewsMay 12 at 5:24 PM | gurufocus.comMoonLake Immunotherapeutics Q1 2025 Earnings: EPS of -$0. ...May 12 at 5:24 PM | gurufocus.comSee More MoonLake Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email. Email Address About MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.View MoonLake Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Upcoming Earnings Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Applied Materials (5/15/2025)Copart (5/15/2025)NetEase (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
